XOMA 052

Phase 2Small molecule

XXOMA (US) LLC

XOMA 052 is one of 86 small molecule programs targeting Muckle-Wells syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Muckle-Wells SyndromeActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Type 1 DiabetesActive, not recruiting

Muckle-Wells SyndromePhase 1/Phase 2

Active, not recruiting

Type 2 Diabetes MellitusPhase 1

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Type 1 DiabetesPhase 2

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Rituxan

Roche

Preclinical

61 2

Enbrel

IImmunex

Preclinical

64 3

Remicade

OOrganon and Co

Preclinical

43 4

XOMA 052

XXOMA (US) LLC

Phase 2

1 5

Ilaris

Novartis

Preclinical

3 6

Celexa

AbbVie

Preclinical

1 7

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 8

Cimzia

UCB

Preclinical

3 9

Certolizumab

Johnson & Johnson

Preclinical

3 10

Disalcid

JJoslin Diabetes Center

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus4 trials

Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus

Completed·XXOMA (US) LLC·Phase 1/2·NCT00513214·68 enrolled

Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus

Completed·XXOMA (US) LLC·Phase 1·NCT00541983·36 enrolled

Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy

Completed·XXOMA (US) LLC·Phase 2·NCT01066715·421 enrolled

Show 1 more trial

Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus

Completed·XXOMA (US) LLC·Phase 2·NCT01144975·76 enrolled

Type 1 Diabetes2 trials

Effects of XOMA 052 on Insulin Production in Type 1 Diabetes

Completed·UUniversity of Zurich·Phase 2·NCT01788033·22 enrolled

Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes

Completed·XXOMA (US) LLC·Phase 2·NCT00998699·22 enrolled

Muckle-Wells syndrome1 trial

A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease

Withdrawn·NNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 1/2·NCT01211977

Rheumatoid Arthritis1 trial

Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis

Suspended·XXOMA (US) LLC·Phase 2·NCT00777816·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for XOMA 052. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XOMA 052 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XOMA 052. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — XOMA (US) LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: XXOMA (US) LLC

XOMA 052

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes Mellitus4 trials

Type 1 Diabetes2 trials

Muckle-Wells syndrome1 trial

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News